3.00
Precedente Chiudi:
$3.11
Aprire:
$3.1
Volume 24 ore:
176.20K
Relative Volume:
0.47
Capitalizzazione di mercato:
$130.81M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.41%
1M Prestazione:
-22.28%
6M Prestazione:
-57.02%
1 anno Prestazione:
+0.00%
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KYTX
Kyverna Therapeutics Inc
|
3.00 | 130.81M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-10 | Iniziato | UBS | Buy |
2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
2024-03-04 | Iniziato | JP Morgan | Overweight |
2024-03-04 | Iniziato | Leerink Partners | Outperform |
2024-03-04 | Iniziato | Morgan Stanley | Overweight |
2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewswire Inc.
KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors - The Bakersfield Californian
Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Kyverna Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesKYTX - PR Newswire
Class Action Filed Against Kyverna Therapeutics, Inc. - GlobeNewswire
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - Morningstar
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Final Deadline for the Kyverna Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsKYTX - PR Newswire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc.KYTX - Business Wire
KYTX FINAL DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
DEADLINE ALERT for BOOM, KYTX, MQ, and SUI: The Law Offices - GlobeNewswire
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-02-03 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Kyverna Therapeutics, Inc. to Contact the Firm Today! | NDAQ:KYTX | Press Release - Stockhouse Publishing
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 13.9% in January - MarketBeat
The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - PR Newswire
Shareholders that lost money on Kyverna Therapeutics, - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - GlobeNewswire
2025-02-02 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:KYTX | Press Release - Stockhouse Publishing
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - PR Newswire
KYTX DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire
KYTX Shareholder Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors - GlobeNewswire
Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact Glancy Prongay & - EIN News
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before February 7, 2025 to Discuss Your RightsKYTX - PR Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ... - The Bakersfield Californian
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure ... - The Hastings Tribune
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna - GlobeNewswire
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - The Eastern Progress Online
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - Victoria Advocate
Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
Kyverna Therapeutics Class Action: How to File a Claim Against the Firm - Lawyer Monthly Magazine
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - PR Newswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - The Malaysian Reserve
Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit - Business Wire
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Non sono disponibili dati finanziari per Kyverna Therapeutics Inc (KYTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Kyverna Therapeutics Inc Azioni (KYTX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
Vida Ventures, LLC | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
253,136 |
5,568,992 |
252,553 |
Bain Capital Life Sciences Inv | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
3,163,868 |
GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
Northpond Ventures III GP, LLC | Former 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
450,000 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):